Home Stock

Stock Research: Xeris Pharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Xeris Pharmaceuticals

NSQ:XERS US98422L1070
73
  • Value
    63
  • Growth
    90
  • Safety
    Safety
    28
  • Combined
    78
  • Sentiment
    56
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing products across a range of therapies. It operates in the biopharmaceutical industry, with main businesses in commercially available products like Recorlev, Gvoke, and Keveyis, and a pipeline of development programs. The description does not specify regions of operation. In the last fiscal year, the company had a market cap of $844 million, profits of $166 million, revenue of $203 million, and 394 employees.

more
Strongest Rank Dividend Yield
Weakest Rank Price vs. Book (P/B)
Country USA
Industry Pharmaceuticals
Size Small
Website xerispharma.com
Index
NASDAQ
Xeris Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
63 63 21 75
Growth
90 79 65 59
Safety
Safety
28 11 18 11
Sentiment
56 68 56 22
360° View
360° View
73 55 25 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
74 100 92 85
Opinions Change
67 36 50 50
Pro Holdings
n/a 57 31 10
Market Pulse
54 47 27 22
Sentiment
56 68 56 22
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
63 63 21 75
Growth
90 79 65 59
Safety Safety
28 11 18 11
Combined
78 50 9 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
57 43 67 56
Price vs. Earnings (P/E)
30 24 24 24
Price vs. Book (P/B)
100 97 1 100
Dividend Yield
1 1 1 1
Value
63 63 21 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
67 78 76 97
Profit Growth
82 34 63 32
Capital Growth
71 81 10 70
Stock Returns
89 75 87 17
Growth
90 79 65 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
18 5 9 21
Refinancing
36 32 55 57
Liquidity
56 31 29 13
Safety Safety
28 11 18 11

Similar Stocks

Discover high‑ranked alternatives to Xeris Pharmaceuticals and broaden your portfolio horizons.

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews